India's drug regulator on Tuesday allowed vaccine maker Serum Institute to enrol children aged 7-11 years for its COVID-19 vaccine trial as the country prepares to protect kids from the coronavirus.
It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion.
"After detailed deliberation, the committee recommended for allowing enrolment of subjects of 7 to 11 years of age group as per the protocol," a subject expert panel of the Central Drugs Standard Control Organisation said.
Serum Institute is already conducting a trial of its COVID-19 vaccine, a domestically produced version of US drugmaker Novavax's shot, in the 12-17 age group and has presented safety data for an initial 100 participants.
So far, only drugmaker Zydus Cadila's DNA COVID-19 vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above.
At least 73 injured after Houthi rebels attack Saudi civilian and energy facilities
Nepal rescue focused on workers trapped in three tunnels
Indonesia reopens Jakarta airport, four others after Anak Krakatau ash clears
Russia hits Kyiv after brief pause for US envoys' visit, killing two
Kenya offers temporary amnesty to undocumented East Africans amid crackdown fears
7 Indonesian airports remain shut due to volcanic ash from Anak Krakatau
Bolivia confirms 9 deaths after military base explosion
Israeli strikes on southern Lebanese town kill 11, state news agency saysÂ
